Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Exp Hematol. 2015 Apr 24;43(7):537–545.e11. doi: 10.1016/j.exphem.2015.03.006

Figure 4. Effect of BMS-911543 on hematopoietic cell lineages in MPN.

Figure 4

Following 42 days of treatment, high dose BMS-911543 reduced the granulocytes (A, Gr1+) and increased the T (CD3+) and B (CD19+/B220+) cells (B and C, respectively) in the spleen, but not the blood or bone marrow (not shown). Flow cytometry data from six vehicle, seven low dose, and seven high dose mice are shown. Error bars represent standard error of the mean. *p≤0.05